Literature DB >> 6812109

Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.

M A Moulin, J P Davy, D Debruyne, J C Andersson, M C Bigot, R Camsonne, E Poilpré.   

Abstract

Haloperidol serum concentrations were determined after IM or oral treatment in 15 schizophrenic patients. No correlation was found between drug levels and therapeutic effect. However, a good relationship was found between the half-life calculated after the first IM injection and the BPRS decrease after 3 weeks. Therefore a serum level study to the first day may forecast the therapeutic response.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6812109     DOI： 10.1007/bf00449123

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  7 in total

1.  Thioridazine plasma levels and clinical response.

Authors:  L A Gottschalk; R Biener; E P Noble; H Birch; D E Wilbert; J F Heiser
Journal:  Compr Psychiatry       Date:  1975 Jul-Aug       Impact factor: 3.735

2.  A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients.

Authors:  A Forsman; E Mårtensson; G Nyberg; R Ohman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

3.  Plasma level profile of haloperidol in man following intramuscular administration.

Authors:  W A Cressman; J R Bianchine; V B Slotnick; P C Johnson; J Plostnieks
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  A gas chromatographic method for the determination of haloperidol in human plasma.

Authors:  I A Zingales
Journal:  J Chromatogr       Date:  1971-01-06

5.  Pharmacokinetic studies on haloperidol in man.

Authors:  A Forsman; R Ohman
Journal:  Curr Ther Res Clin Exp       Date:  1976-09

6.  High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.

Authors:  N Bjørndal; M Bjerre; J Gerlach; P Kristjansen; G Magelund; I H Oestrich; J Waehrens
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

7.  Haloperidol plasma level monitoring in psychiatric patients.

Authors:  P L Morselli; E Zarifian; H Cuche; G Bianchetti; M J Cotterau; P Deniker
Journal:  Adv Biochem Psychopharmacol       Date:  1980
  7 in total
  4 in total

1.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 2.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 3.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

4.  Haloperidol plasma levels and clinical response in paranoid schizophrenics.

Authors:  P Linkowski; P Hubain; R von Frenckell; J Mendlewicz
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.